Development of an escherichia coli expressing listeriolysin-o vaccine against wilms tumor gene 1-expressing tumors

Ming Shen Dai, Josianne Nitcheu-Tefit, Sally Alcock, Francisco Ramirez-Jimenez, Tsu Yi Chao, Patrick Baril, Marian Rocha, Sara J. Brett, Hans J. Stauss, Georges Vassaux

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Through their ability to induce cytotoxic T-lymphocytes and inhibit Foxp3 T-regulatory cells, Escherichia coli expressing listeriolysin-O (LLO) and a model tumor antigen have been shown to exert strong antitumor activity. The aim of this study is to extend these observations to a self-protein and clinically relevant tumor antigen associated with most types of adult leukemia: Wilms tumor gene 1 (WT1). We demonstrate that an E. coli coexpressing LLO and WT1 is capable of inducing a strong antitumor effect against WT1-expressing tumors in vivo through its ability to induce cytotoxic T-lymphocytes and inhibit the function of Foxp3 T-regulatory cells. Furthermore, we have characterized the immunodominant epitope involved in this effect (NAPYLPSCL) and demonstrated that coinjection of NAPYLPSCL with E. coli-LLO resulted in an antitumor effect largely equivalent to that obtained with E. coli-LLO/WT1. Our data demonstrate that the results obtained with a clinically irrelevant model tumor antigen remain valid with a "real" tumor antigen and that the adjuvant properties of the E. coli-LLO vaccine can be exploited in conjunction with peptides. The results obtained in this study will facilitate the translation of this work to human studies by combining antigenic motifs relevant to specific human leukocyte antigen haplotypes with the adjuvant effect of E. coli-LLO.

Original languageEnglish
Pages (from-to)845-855
Number of pages11
JournalJournal of Immunotherapy
Volume32
Issue number8
DOIs
Publication statusPublished - Oct 2009
Externally publishedYes

Fingerprint

Wilms' Tumor Genes
Wilms Tumor
Vaccines
Neoplasm Antigens
Escherichia coli
Neoplasms
Cytotoxic T-Lymphocytes
Regulatory T-Lymphocytes
Immunodominant Epitopes
HLA Antigens
Haplotypes
Listeria monocytogenes hlyA protein
Leukemia
Peptides

Keywords

  • E. coli
  • Leukemia
  • Listeriolysin-O
  • Wilms tumor gene 1 (WT1)

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Cancer Research
  • Pharmacology

Cite this

Development of an escherichia coli expressing listeriolysin-o vaccine against wilms tumor gene 1-expressing tumors. / Dai, Ming Shen; Nitcheu-Tefit, Josianne; Alcock, Sally; Ramirez-Jimenez, Francisco; Chao, Tsu Yi; Baril, Patrick; Rocha, Marian; Brett, Sara J.; Stauss, Hans J.; Vassaux, Georges.

In: Journal of Immunotherapy, Vol. 32, No. 8, 10.2009, p. 845-855.

Research output: Contribution to journalArticle

Dai, MS, Nitcheu-Tefit, J, Alcock, S, Ramirez-Jimenez, F, Chao, TY, Baril, P, Rocha, M, Brett, SJ, Stauss, HJ & Vassaux, G 2009, 'Development of an escherichia coli expressing listeriolysin-o vaccine against wilms tumor gene 1-expressing tumors', Journal of Immunotherapy, vol. 32, no. 8, pp. 845-855. https://doi.org/10.1097/CJI.0b013e3181aee259
Dai, Ming Shen ; Nitcheu-Tefit, Josianne ; Alcock, Sally ; Ramirez-Jimenez, Francisco ; Chao, Tsu Yi ; Baril, Patrick ; Rocha, Marian ; Brett, Sara J. ; Stauss, Hans J. ; Vassaux, Georges. / Development of an escherichia coli expressing listeriolysin-o vaccine against wilms tumor gene 1-expressing tumors. In: Journal of Immunotherapy. 2009 ; Vol. 32, No. 8. pp. 845-855.
@article{6a477fa61f9f4362ad6969069d576b9d,
title = "Development of an escherichia coli expressing listeriolysin-o vaccine against wilms tumor gene 1-expressing tumors",
abstract = "Through their ability to induce cytotoxic T-lymphocytes and inhibit Foxp3 T-regulatory cells, Escherichia coli expressing listeriolysin-O (LLO) and a model tumor antigen have been shown to exert strong antitumor activity. The aim of this study is to extend these observations to a self-protein and clinically relevant tumor antigen associated with most types of adult leukemia: Wilms tumor gene 1 (WT1). We demonstrate that an E. coli coexpressing LLO and WT1 is capable of inducing a strong antitumor effect against WT1-expressing tumors in vivo through its ability to induce cytotoxic T-lymphocytes and inhibit the function of Foxp3 T-regulatory cells. Furthermore, we have characterized the immunodominant epitope involved in this effect (NAPYLPSCL) and demonstrated that coinjection of NAPYLPSCL with E. coli-LLO resulted in an antitumor effect largely equivalent to that obtained with E. coli-LLO/WT1. Our data demonstrate that the results obtained with a clinically irrelevant model tumor antigen remain valid with a {"}real{"} tumor antigen and that the adjuvant properties of the E. coli-LLO vaccine can be exploited in conjunction with peptides. The results obtained in this study will facilitate the translation of this work to human studies by combining antigenic motifs relevant to specific human leukocyte antigen haplotypes with the adjuvant effect of E. coli-LLO.",
keywords = "E. coli, Leukemia, Listeriolysin-O, Wilms tumor gene 1 (WT1)",
author = "Dai, {Ming Shen} and Josianne Nitcheu-Tefit and Sally Alcock and Francisco Ramirez-Jimenez and Chao, {Tsu Yi} and Patrick Baril and Marian Rocha and Brett, {Sara J.} and Stauss, {Hans J.} and Georges Vassaux",
year = "2009",
month = "10",
doi = "10.1097/CJI.0b013e3181aee259",
language = "English",
volume = "32",
pages = "845--855",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Development of an escherichia coli expressing listeriolysin-o vaccine against wilms tumor gene 1-expressing tumors

AU - Dai, Ming Shen

AU - Nitcheu-Tefit, Josianne

AU - Alcock, Sally

AU - Ramirez-Jimenez, Francisco

AU - Chao, Tsu Yi

AU - Baril, Patrick

AU - Rocha, Marian

AU - Brett, Sara J.

AU - Stauss, Hans J.

AU - Vassaux, Georges

PY - 2009/10

Y1 - 2009/10

N2 - Through their ability to induce cytotoxic T-lymphocytes and inhibit Foxp3 T-regulatory cells, Escherichia coli expressing listeriolysin-O (LLO) and a model tumor antigen have been shown to exert strong antitumor activity. The aim of this study is to extend these observations to a self-protein and clinically relevant tumor antigen associated with most types of adult leukemia: Wilms tumor gene 1 (WT1). We demonstrate that an E. coli coexpressing LLO and WT1 is capable of inducing a strong antitumor effect against WT1-expressing tumors in vivo through its ability to induce cytotoxic T-lymphocytes and inhibit the function of Foxp3 T-regulatory cells. Furthermore, we have characterized the immunodominant epitope involved in this effect (NAPYLPSCL) and demonstrated that coinjection of NAPYLPSCL with E. coli-LLO resulted in an antitumor effect largely equivalent to that obtained with E. coli-LLO/WT1. Our data demonstrate that the results obtained with a clinically irrelevant model tumor antigen remain valid with a "real" tumor antigen and that the adjuvant properties of the E. coli-LLO vaccine can be exploited in conjunction with peptides. The results obtained in this study will facilitate the translation of this work to human studies by combining antigenic motifs relevant to specific human leukocyte antigen haplotypes with the adjuvant effect of E. coli-LLO.

AB - Through their ability to induce cytotoxic T-lymphocytes and inhibit Foxp3 T-regulatory cells, Escherichia coli expressing listeriolysin-O (LLO) and a model tumor antigen have been shown to exert strong antitumor activity. The aim of this study is to extend these observations to a self-protein and clinically relevant tumor antigen associated with most types of adult leukemia: Wilms tumor gene 1 (WT1). We demonstrate that an E. coli coexpressing LLO and WT1 is capable of inducing a strong antitumor effect against WT1-expressing tumors in vivo through its ability to induce cytotoxic T-lymphocytes and inhibit the function of Foxp3 T-regulatory cells. Furthermore, we have characterized the immunodominant epitope involved in this effect (NAPYLPSCL) and demonstrated that coinjection of NAPYLPSCL with E. coli-LLO resulted in an antitumor effect largely equivalent to that obtained with E. coli-LLO/WT1. Our data demonstrate that the results obtained with a clinically irrelevant model tumor antigen remain valid with a "real" tumor antigen and that the adjuvant properties of the E. coli-LLO vaccine can be exploited in conjunction with peptides. The results obtained in this study will facilitate the translation of this work to human studies by combining antigenic motifs relevant to specific human leukocyte antigen haplotypes with the adjuvant effect of E. coli-LLO.

KW - E. coli

KW - Leukemia

KW - Listeriolysin-O

KW - Wilms tumor gene 1 (WT1)

UR - http://www.scopus.com/inward/record.url?scp=70349690555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349690555&partnerID=8YFLogxK

U2 - 10.1097/CJI.0b013e3181aee259

DO - 10.1097/CJI.0b013e3181aee259

M3 - Article

VL - 32

SP - 845

EP - 855

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 8

ER -